Poster

Explore our recent poster presentation, which discusses the challenge of identifying predictive biomarkers for cytokine-based immunotherapy in head and neck cancers due to the complexity of biological systems and cancer pathophysiology. It highlights the importance of understanding how drugs interact with different biomarkers and tissues spatially to improve trial success rates, reduce costs, and accelerate completion times.

By analyzing spatial and temporal changes in tumor cells and their microenvironment, you can uncover resistance mechanisms, leading to the design of more effective combination therapies. The Aliri solution offers enhanced tumor profiling through spatial analysis, integration of heterogenous data types, and predictive analysis, ultimately identify robust biomarker signatures for improved immunotherapy outcomes.

Download our poster to gain insights into the unique biomarker signatures correlated with therapy response.

Dive into the complex landscape of immune checkpoint inhibitors (ICIs) in lung cancer in our poster presentation. 
 
As the use of immunotherapy in early-stage non-small cell lung cancer (NSCLC) remains a challenge, we offer a spatially-informed approach to identify useful biomarkers. By using spatial biomarker assays, and analysis involving spatial transcriptomics and proteomics, we reveal the cell-to-cell interactions in the tumor microenvironment.  
 
Download our poster to explore our findings and gain insights into the suitability of ICIs for personalized therapy

Explore the spatial organization of tertiary lymphoid structures (TLS) in non-small cell lung cancer (NSCLC) and its impact on ant-PD-1 treatment response in our poster presentation.  
 
Using high-plex imaging mass cytometry staining, we investigated the relationship between TLS spatial organization, the tumor microenvironment, and patient response to therapy. We leveraged deep learning for cell segmentation and characterization to identify that the presence of tumor-associated TLS correlates with a positive response to ant-PD-1 therapy.  
  
Download our poster to dive into this spatial distribution insight and its potential impact on immunotherapies.

Explore our recent poster presentation, which dives into a highly sensitive analysis using an EVOSEP-LC-MS/MS assay, with a focus on targeted PD-L1 and PD-1 expression levels to predict responses to immune checkpoint inhibitors (ICIs). 
 
We address the limitations of traditional PD-L1 and PD-1 immunoassays and their uncertain clinical value across tumor types. Through analysis of our robust method against routine immunoassays, and use of Overall Response Rate (ORR), we offer a new perspective on the predictive power of biomarkers for non-small cell lung cancer (NSCLC) therapy.  
 
Download our poster to discover the potential of this innovative approach.  

Quantitative MALDI Mass Spectrometry Imaging (QSMI) can be used to determine drug distribution in first-in-human studies

At WRIB 2023, Shane Karnik, Senior Laboratory Director at Aliri, presented a poster about utilizing QSMI to determine Bimiralizib distribution in human skin biopsies.

Recent clinical trial results validate Bimiralizib distribution in human skin and showcase:

• Robustness of MALDI MSI method 
• Approach not limited to dermatology; already applied in oncology
• Absolute quantification allowed to determine if the compound reached the site of action  
• Method allows to characterize small compound PK in clinical trial
• Method allows the characterization of the target engagement 

Download our poster about utilizing QSMI to determine drug distribution.